Oncolytic Viral Therapy for Bladder Cancer

Inquiry

Oncolytic viruses are a unique class of therapeutic agents that possess the remarkable ability to selectively infect and destroy cancer cells, while leaving healthy tissues unharmed. As a premier preclinical CRO, Alfa Cytology offers comprehensive services in the development and evaluation of oncolytic viral for bladder cancer therapy.

Introduction to Oncolytic Viral Therapy

In the context of bladder cancer, oncolytic viral therapy holds immense promise. Bladder tumors are often highly accessible, making them an ideal target for direct viral administration. Additionally, the bladder's unique anatomical and immunological features can be leveraged to enhance the efficacy of oncolytic viral therapies.

Fig.1 Proposed antitumor mechanisms of oncolytic viruses in bladder cancer. (Hu H., et al. 2022)

Oncolytic viruses can exert their antitumor effects through various mechanisms, each of which contributes to the overall therapeutic potential of this approach:

Direct Oncolysis	Stimulation of Antitumor Immunity
Oncolytic viruses can directly induce apoptosis, necrosis, or other forms of cell death in bladder cancer cells through their replication cycle.	Viral infection can lead to the release of tumor-associated antigens and danger signals, which can stimulate a robust antitumor immune response.
Inhibition of Angiogenesis	Vascular Disruption
Oncolytic viruses may also be capable of inhibiting the formation of new blood vessels that feed the tumor, thereby depriving the malignant cells of the oxygen and nutrients they require for survival and growth.	Some oncolytic viruses have the ability to selectively disrupt the tumor vasculature, leading to reduced blood supply and oxygen delivery to the malignant cells.

Oncolytic Virus Therapy Development for Bladder Cancer

Researchers have extensively investigated a diverse array of viruses, including adenoviruses, herpes simplex virus, coxsackievirus, Newcastle disease virus, vesicular stomatitis virus, alphavirus, and vaccinia virus, to evaluate their potential as oncolytic agents against this malignancy.

Virus (Alias)	Parent Virus	Trial Identifier
CAVATAK	Adenovirus	NCT02316171
CG0070	Adenovirus	NCT00109655
CG0070	Adenovirus	NCT02365818
CG0070	Adenovirus	NCT04387461
CG0070	Adenovirus	NCT04452591
OH2	HSV-2	NCT05232136
MV-NIS	Measles virus	NCT03171493
Enadenotucirev	Adenovirus	NCT02053220
Enadenotucirev	Adenovirus	NCT02028442
CVA21	Coxsackievirus	NCT02043665
CAdVEC	Adenovirus	NCT03740256
OH2	HSV-2	NCT05248789
PF-07263689	Vaccinia virus	NCT05061537
YSCH-01	Adenovirus	NCT05180851

Our Services

At Alfa Cytology, utilize our proprietary manufacturing technology to provide solutions for the rapid development of oncolytic agents for bladder cancer. Our services cover everything from virus engineering and cell biology to animal testing. Various types of oncolytic virus engineering systems have been established in-house to facilitate the development of oncolytic virus therapies in a shorter time and at a lower budget.

Oncolytic Adenovirus Development

Oncolytic Herpes Simplex Virus (HSV) Development

Oncolytic Coxsackievirus Development

Oncolytic Alphavirus Development

Oncolytic Vaccinia Virus Development

Oncolytic Reovirus Development

Oncolytic Vesicular Stomatitis Virus (VSV) Development

Oncolytic Newcastle Disease Virus (NDV) Development

Contact Us

If you are interested in exploring the potential of oncolytic viral therapy for bladder cancer, we invite you to contact Alfa Cytology. Our cancer experts have many years of experience in the latest therapies for oncolytic viral therapy.

Reference

Hu H., Xia Q., and et al. Oncolytic Viruses for the Treatment of Bladder Cancer: Advances, Challenges, and Prospects. J Clin Med. 2022, 11(23): 6997.

For research use only. Not intended for any clinical use.

Related Services

Solutions

Inquiry

* Name:

* Email:

Phone:

* Services:

Description:

* Please note that we are not a pharmacy or clinic, so we do not offer diagnostic and treatment services for patients.

* Tick to confirm the Research Use Only (RUO) statement.